Astonea Labs Approves Financial Results for FY2025-26, Considers Strategic Expansion and Director Reappointment
Astonea Labs Limited (Company) announced significant corporate approvals following its Board of Directors meeting held on July 24, 2026. The Board approved the Audited Consolidated Financial Results and Annual Report for the financial year ended March 31, 2026, alongside several strategic decisions related to business expansion, governance structure, and future operational planning.The Board thoroughly reviewed and adopted the Draft Board's Report and the Annual Report for the fiscal year ending March 31, 2026, which included the Audited Financial Statements, Statutory Auditors' Report, and various statements and disclosures. The Consolidated Financial Results were approved after the completion of the audit process and the receipt of the audited financial statements from its associate company, Damaira Pharmaceuticals Private Limited.
The company’s results for the fiscal year ended March 31, 2026, demonstrated strong performance. Key financial highlights include:
| Metric | FY Ended 31 Mar, 2026 (Audited) | FY Ended 31 Mar, 2025 (Audited) |
|---|---|---|
| Revenue from Operations | 14,758.44 (lakhs) | 9,751.83 (lakhs) |
| Total Income | 14,810.43 (lakhs) | 9,770.77 (lakhs) |
| Total Expenses | 10,278.62 (lakhs) | 5,705.89 (lakhs) |
| Profit/(Loss) for the Year, Net of Tax | 535.05 (lakhs) | 707.11 (lakhs) |
The Consolidated Statement of Audited Assets and Liabilities as at March 31, 2026, showed total liabilities of 14,626.00, compared to 10,338.07 in the previous year. The company’s current assets stood at 14,626.00 on that date.
Strategic and Governance Updates
Business Object Alteration and Expansion:The Board approved the proposal for altering the Object Clause (Clause III(A)) of the Memorandum of Association (MOA). This alteration permits the company to expand its operations across manufacturing, formulation, processing, development, refining, import, export, wholesale, and retail trading of pharmaceuticals, medicines, healthcare products, nutraceuticals, ayurvedic, herbal, and dietary supplement products. The approved changes also include marketing, promotion, distribution, and sale through various lawful channels, including e-commerce platforms and franchise arrangements. This alteration requires approval by shareholders via a Special Resolution at the upcoming General Meeting.
Investment in Subsidiaries:
The Board also approved the proposal for incorporation, promotion, and investment into one or more subsidiary company(ies) in India to enhance operational efficiency and explore new business opportunities. The company is currently engaged in the manufacture and sale of cosmetics and pharmaceutical products as a single segment, with export sales noted as a secondary geographic segment.
Director Appointment:
The Board took note of the retirement by rotation of Ms. Pooja Singh (DIN: 10547745). In due consideration, the Board recommended her for re-appointment at the ensuing Annual General Meeting, noting that she is eligible and has submitted consent and requisite declarations.
Annual General Meeting Details:
The notice for the 9th Annual General Meeting (AGM) was approved. The AGM is scheduled for Friday, August 21, 2026, at 11:30 A.M. at Mercure Hotel in Chandigarh. The Board also approved the appointment of National Securities Depository Limited (NSDL) as the e-voting agency and Mr. Sahil Malhotra (Membership No. A38204 / COP No. 14791) as the Scrutinizer for the AGM.
Financial Management:
The Board addressed various operational matters, including deferring the termination of specific agreements with Astonea One Private Limited, and approved the re-appointment of M/s Avnish Sharma & Associates, Chartered Accountants (Firm Registration No. 009398N), as the Tax Auditor for the Tax Year 2026-27.
Audit Findings and Commitments
The Statutory Auditors issued an unmodified opinion on the Audited Consolidated Financial Results for the Half-Year and Financial Year ended March 31, 2026. The audit noted that the consolidated results include the share of profit from associate company Damaira Pharmaceuticals Private Limited (25.74% of Rs. 42,12,220 for one day).The Notes to Consolidated Audited Financial Results included points of emphasis, including a major fire incident on April 27, 2026, which caused substantial damage to the factory premises and stocks. The company reported an estimated loss of Rs 9.39 crores regarding this incident.
Stock Price Movement
Closing out the day, Astonea Labs Ltd saw its shares settle at ₹266.05, marking a 1.64% gain. The stock traded within a tight intraday range, moving between a low of ₹266.00 and a high of ₹266.05.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: